The FDA just approved a new type of pain medication, and it's a non-opioid called suzetrigine that stops body pain at its ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Dr. Gilbert J. Zoghbi, MD. FACC, FSCAI discusses renal denervation therapy, a new FDA-approved treatment for resistant ...

( The Hill) – The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first ...

With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...

If you’re dealing with depression or anxiety, relief can sometimes be hard to find. At Sunrise Psychiatry Inc, Dr. Sonni ...

HIV has become a more manageable condition in recent years, but a full cure remains elusive. Now, scientists have found ...

The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and ...

The new drug will carry a list price of $15.50 per pill, making it many times more expensive than comparable opioids.

The following is a summary of “A year in review: new treatments and expanded indications in dermatology in 2024,” published in the January 2025 issue of Dermatology by McGrath et al. In 2024, ...

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) stock is up 6% at $465.02 at last glance, after the U.S. Food and Drug ...

Panelists discuss how modern FDA-approved intravenous iron formulations, including ferric carboxymaltose, ferumoxytol, and ...